HC 58Alternative Names: Elcatonin-Asahi Kasei Pharma; HC-58
Latest Information Update: 24 Dec 2015
At a glance
- Originator Asahi Kasei Pharma Corp
- Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
- Mechanism of Action Calcitonin receptor agonists; Osteogenesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Hemiplegia
Most Recent Events
- 31 Jul 2015 Phase-II development is ongoing in Japan